New Data Affirms Strength of UCB Immuno-Dermatology Portfolio

Corporate Communications

France Nivelle,                  Global Communications, UCB

T +32.2.559.9178, [email protected]  

Investor Relations

Antje Witte,                      Investor Relations, UCB

T +32.2.559.94.14, [email protected]

Brand Communications

Andrea Levin Christopher,Immunology Communications, UCB

T +1.404.483.7329

[email protected]

Laurent Schots,

Media Relations, UCB   

T+32.2.559.92.64, [email protected]